NCT05172518尚未招募3 期
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer : A Phase III, Open-label, Randomized Controlled Trial
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 512 人开始时间: 2022年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 512
- 试验地点
- 1
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form;
- •Women aged ≥ 18 years;
- •Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;
- •The primary tumor and metastases (if aspirated) are both HER2-negative;
- •Eastern Cooperative Oncology Group (ECOG) score [0-2] points;
- •Measurable disease according to RECIST version 1.1;
- •Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomisation;
- •No more than one prior chemotherapy regimen for inoperable locally advanced or metastatic HER2-negative breast cancer;
- •Hormone receptor positive patients are allowed no more than two lines of prior endocrine therapy for metastatic disease (including CDK4/6 inhibitors, chidamide and PI3K inhibitors, etc.);
- •Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia are allowed ;
- •Patients with asymptomatic CNS metastases may be enrolled, if:
- •Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or
- •Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ;
- •Adequate hematological, hepatic and renal function;
- •Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment;
- •Life expectancy of at least 12 weeks;
- •Patients must be able to participate and comply with treatment and follow-up.
排除标准
- •HER-2 positive (IHC + + +, or FISH positive);
- •Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;
- •Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, hormone therapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy;
- •Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study;
- •Symptomatic peripheral neuropathy or CTCAE 5.0 grade ≥ 2;
- •Experienced grade 3 or above nervous system-related adverse events after treatment with anti-microtubule drugs;
- •Received taxane and/or capecitabine-containing adjuvant/neoadjuvant chemotherapy within 1 year prior to the first study treatment;
- •Received prior first-line chemotherapy containing a taxane or capecitabine;
- •Symptomatic central nervous system metastases;
- •Inability to take or absorb oral medications;
- •Pregnant or lactating women;
- •Known or suspected hypersensitivity to any of the study drugs or excipients;
- •Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ；
- •Any other condition that the investigator considers inappropriate to participate in this trial .
- •Use of corticosteroids is prohibited.
研究组 & 干预措施
Arm A
Active Comparator
Taxane plus Intermittent Capecitabine
干预措施: Taxane plus Intermittent Capecitabine (Drug)
Arm B
Experimental
Utidelone plus Intermittent Capecitabine
干预措施: Utidelone plus Intermittent Capecitabine (Drug)
Arm C
Active Comparator
Taxane plus Metronomic Capecitabine
干预措施: Taxane plus Metronomic Capecitabine (Drug)
Arm D
Experimental
Utidelone plus Metronomic Capecitabine
干预措施: Utidelone plus Metronomic Capecitabine (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: up to 60 months
Time from randomization to progression or death (whichever occurred first).
次要结局
- Objective response rate (ORR)(up to 60 months)
- Overall survival (OS)(up to 60 months)
- Time to response (TTR)(up to 60 months)
- Duration of response (DOR)(up to 60 months)
研究者
wang shusen
Chief Physician
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric JunctionGastric CancerNCT01468389The Affiliated Hospital of the Chinese Academy of Military Medical Sciences300
已完成
3 期
Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast CancerBreast CancerNCT02253459Beijing Biostar Pharmaceuticals Co., Ltd.405
招募中
3 期
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast CancerBreast CancerNCT05673629Beijing Biostar Pharmaceuticals Co., Ltd.552
招募中
2 期
Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast CancerBreast Cancer RecurrentNCT06458413Min Yan, MD40
进行中（未招募）
3 期
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerHER2 Positive Breast CancerNCT05132582Seagen, a wholly owned subsidiary of Pfizer654